News

Aurobindo Pharma has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets, 5 mg and 10 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xeljanz Tablets, 5 mg and 10 mg, of PF Prism C.V. The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately.

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-I, a formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, 500078, Telangana, from February 16 to February 27, 2026. The inspection had concluded with 4 observations. FDA has now determined that the inspection classification of this facility is �official action indicated� (OAI).

Net profit of Aurobindo Pharma rose 1.97% to Rs 921.26 crore in the quarter ended March 2026 as against Rs 903.47 crore during the previous quarter ended March 2025. Sales rose 4.42% to Rs 8751.50 crore in the quarter ended March 2026 as against Rs 8381.12 crore during the previous quarter ended March 2025.For the full year,net profit rose 0.54% to Rs 3504.75 crore in the year ended March 2026 as against Rs 3485.88 crore during the previous year ended March 2025. Sales rose 6.39% to Rs 33384.74 crore in the year ended March 2026 as against Rs 31378.13 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales8751.508381.12 4 33384.7431378.13 6 OPM %20.0021.00 -20.5120.88 - PBDT1769.181779.52 -1 6955.376715.71 4 PBT1290.611335.09 -3 5177.185066.29 2 NP921.26903.47 2 3504.753485.88 1 Powered by Capital Market - Live News

Aurobindo Pharma announced that CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva�, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ`s facility in Hyderabad and marketing of Bevqolva� in 100 mg/4mL and 400 mg/16 mL vial presentations.

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 21 May 2026.